<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00149552</url>
  </required_header>
  <id_info>
    <org_study_id>NIDA-14966-1</org_study_id>
    <secondary_id>R01DA014966</secondary_id>
    <nct_id>NCT00149552</nct_id>
  </id_info>
  <brief_title>Zinc Therapy in HIV Infected Individuals Who Abuse Drugs</brief_title>
  <official_title>Zinc Therapy in Zinc Deficient HIV Positive Drug Users</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Florida International University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Florida International University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Zinc deficiency is prevalent in HIV infected individuals who abuse drugs. The purpose of this
      study is to determine if zinc therapy will prevent immune failure in HIV infected individuals
      who abuse drugs and have low plasma zinc levels.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Low levels of zinc are associated with an increased risk of HIV-related death and
      opportunistic infections in HIV infected individuals. Drug users are especially susceptible
      to zinc deficiency. The purpose of this trial is to evaluate the effectiveness of zinc
      therapy in preventing immune failure in HIV infected individuals who abuse drugs.

      This trial will last 30 months. Participants will be randomly assigned to receive either zinc
      supplements or placebo. Male participants will receive 15 mg of zinc and female participants
      will receive 12 mg of zinc. Clinical and laboratory study visits will occur at 3 or 6 month
      intervals throughout the study.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2001</start_date>
  <completion_date type="Actual">January 2007</completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Immune failure</measure>
    <time_frame>For at least 6 months</time_frame>
    <description>CD4 cell count &lt;200 cells/uL</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Morbidity</measure>
    <time_frame>For at least 6 months</time_frame>
    <description>AIDS related morbidity</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">231</enrollment>
  <condition>HIV Infections</condition>
  <condition>Substance-Related Disorders</condition>
  <arm_group>
    <arm_group_label>Zinc gluconate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Zinc supplementation</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>zinc</intervention_name>
    <description>supplementation with zinc gluconate</description>
    <arm_group_label>Zinc gluconate</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV infected

          -  Drug User

          -  Blood zinc level greater than 0.35 mcg/mL and less than 0.75mcg/ml

        Exclusion Criteria:

          -  Currently participating in an another clinical trial

          -  Blood selenium level less than 85 mcg/L

          -  Pregnant or intends to become pregnant
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Marianna K. Baum, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Florida International University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Camillus House</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 6, 2005</study_first_submitted>
  <study_first_submitted_qc>September 6, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 8, 2005</study_first_posted>
  <last_update_submitted>March 1, 2012</last_update_submitted>
  <last_update_submitted_qc>March 1, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Florida International University</investigator_affiliation>
    <investigator_full_name>Marianna Baum</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Treatment Naive</keyword>
  <keyword>Treatment Experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Zinc</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

